Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Rhythm Pharmaceuticals Inc 222 BERKELEY STREET 12TH FLOOR BOSTON MA 02116 USA

www.rhythmtx.com P: 857-264-4280 F: 857-264-4299

Description:

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA.

Key Statistics

Overview:

Market Capitalization, $K 2,388,159
Enterprise Value, $K 2,328,079
Shares Outstanding, K 60,140
Annual Sales, $ 77,430 K
Annual Net Income, $ -184,680 K
Last Quarter Sales, $ 24,230 K
Last Quarter Net Income, $ -41,630 K
EBIT, $ -184,350 K
EBITDA, $ -169,230 K
60-Month Beta 1.90
% of Insider Shareholders 4.70%
Float, K 57,313
% Float 95.30%
Short Volume Ratio 0.71

Growth:

1-Year Return 80.80%
3-Year Return 84.18%
5-Year Return 55.30%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -33.89%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.70 on 02/22/24
Latest Earnings Date 05/07/24
Earnings Per Share ttm -3.20
EPS Growth vs. Prev Qtr 7.89%
EPS Growth vs. Prev Year 6.67%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

RYTM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -96.02%
Return-on-Assets % -55.02%
Profit Margin % -238.51%
Debt/Equity 0.00
Price/Sales 31.07
Price/Cash Flow N/A
Price/Book 13.58
Book Value/Share 2.87
Interest Coverage -12.25
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar